Literature DB >> 15164944

Cerebrospinal fluid S-100 protein levels in neurological pathologies.

J R Infante1, A Martínez, J Ochoa, F Cañadillas, M Torres-Avisbal, J A Vallejo, F M González, C Pacheco, J M Latre.   

Abstract

The aim of this paper was to evaluate S-100 concentration in cerebrospinal fluid (CSF) from patients with different neurological disorders, and in subjects with no proven neurological pathology, in order to study possible differences in their protein concentrations. The total number of patient-samples examined was 119 (58 males and 61 females; mean age 35 yrs, 1-79 yrs). Based on the final diagnoses, nine patient groups were studied: a control group, meningitis, acute lymphatic leukemia (ALL), dementia, hydrocephalia, polyneuropathy-motor neuron disease, acute cerebral infarction (ACI), and patients diagnosed with multiple sclerosis. S-100 protein concentrations were measured by the Sangtec 100 two-site immunoradiometric assay. The highest S-100 levels in CSF were found in the dementia group, ACI group, bacterial-fungal and lymphocytic meningitis groups (Kruskal-Wallis test). The S-100 concentrations in these groups were significantly higher compared with the control group (Mann-Whitney U test, p<0.05, p<0.01) and the multiple sclerosis group (p<0.05, p<0.01). No other significant differences were found between groups. Our results suggest that the high protein levels in CSF found in these pathologies may reflect the presence of brain damage. However, the levels need to be considered individually, as they depend on several factors, such as age, severity of brain damage or interval between the onset of brain damage and the taking of the sample.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15164944     DOI: 10.1007/bf03179882

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  19 in total

1.  Evaluation of tumor marker S-100 in cerebrospinal fluid from subjects with nonischemic brain pathologies.

Authors:  J R Infante; M Torres-Avisbal; A Martinez; J A Vallejo; C Aguilera; P Contreras; A Benitez; J M Latre
Journal:  Tumour Biol       Date:  2000 Jan-Feb

2.  Monitoring malignant melanoma with the S-100B tumour marker.

Authors:  J M Bonfrer; C M Korse
Journal:  Recent Results Cancer Res       Date:  2001

3.  S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction.

Authors:  T Büttner; S Weyers; T Postert; R Sprengelmeyer; W Kuhn
Journal:  Stroke       Date:  1997-10       Impact factor: 7.914

4.  Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia.

Authors:  A J Green; R J Harvey; E J Thompson; M N Rossor
Journal:  Neurosci Lett       Date:  1997-10-10       Impact factor: 3.046

5.  S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.

Authors:  A Hauschild; G Engel; W Brenner; R Gläser; H Mönig; E Henze; E Christophers
Journal:  Oncology       Date:  1999       Impact factor: 2.935

6.  S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Authors:  M Otto; H Stein; A Szudra; I Zerr; M Bodemer; O Gefeller; S Poser; H A Kretzschmar; M Mäder; T Weber
Journal:  J Neurol       Date:  1997-09       Impact factor: 4.849

7.  S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.

Authors:  L Persson; H G Hårdemark; J Gustafsson; G Rundström; I Mendel-Hartvig; T Esscher; S Påhlman
Journal:  Stroke       Date:  1987 Sep-Oct       Impact factor: 7.914

8.  Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction.

Authors:  A Aurell; L E Rosengren; B Karlsson; J E Olsson; V Zbornikova; K G Haglid
Journal:  Stroke       Date:  1991-10       Impact factor: 7.914

9.  Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid.

Authors:  C J Sindic; M P Chalon; C L Cambiaso; E C Laterre; P L Masson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

10.  Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases.

Authors:  K Mokuno; K Kato; K Kawai; Y Matsuoka; T Yanagi; I Sobue
Journal:  J Neurol Sci       Date:  1983 Aug-Sep       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.